Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Thoracic Oncology
Volume 14 - 2024 | doi: 10.3389/fonc.2024.1445668

Single Gene Testing and Comprehensive Genomic Profiling in Non-Small Cell Lung Cancer: A Case Series of Divergent Results from a Large Reference Laboratory

Provisionally accepted
Kyle C. Strickland Kyle C. Strickland 1,2*Mary K. Nesline Mary K. Nesline 1Rebecca A. Previs Rebecca A. Previs 1,2Heidi Ko Heidi Ko 1Maureen Cooper Maureen Cooper 1Jennifer R. Rushton Jennifer R. Rushton 3Zachary D. Wallen Zachary D. Wallen 1Sarbjot Pabla Sarbjot Pabla 1Jeffrey M. Conroy Jeffrey M. Conroy 1Mark Sausen Mark Sausen 1Kamal S. Saini Kamal S. Saini 4,5Luca Cantini Luca Cantini 4Taylor J. Jensen Taylor J. Jensen 1Brian J. Caveney Brian J. Caveney 1Marcia Eisenberg Marcia Eisenberg 1Eric A. Severson Eric A. Severson 1Shakti Ramkissoon Shakti Ramkissoon 1,6
  • 1 Labcorp Oncology, Durham, United States
  • 2 Duke University Medical Center, Duke University, Durham, North Carolina, United States
  • 3 Baptist Health System, San Antonio, Texas, United States
  • 4 Fortrea Inc., Durham, North Carolina, United States
  • 5 Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, United Kingdom
  • 6 Comprehensive Cancer Center, School of Medicine, Wake Forest University, Winston-Salem, North Carolina, United States

The final, formatted version of the article will be published soon.

    Clinical management of non-small cell lung cancer (NSCLC) requires accurate identification of tumor-specific genetic alterations to inform treatment options. Historically, providers have relied on single-gene testing (SGT) for actionable variants due to a perception of cost-effectiveness and/or efficient turnaround time compared to next-generation sequencing (NGS). However, not all actionable variants may be evaluated through SGT modalities, and an SGT approach can exhaust valuable tissue needed for more comprehensive analyses. In contrast, comprehensive genomic profiling (CGP) tests employ NGS to sequence megabases of DNA and RNA to evaluate all relevant molecular alterations, providing a broader genetic profile to identify actionable alterations that SGT may not accurately or efficiently assess. Here, we briefly describe four cases from a large reference laboratory in which actionable alterations were identified by CGP but not SGT. The discussion highlights the utility and advantages of using CGP to provide complete and timely treatment options and clinical trial opportunities for patients with NSCLC.

    Keywords: non-small cell lung cancer (NSCLC) molecular testing, single gene testing (SGT), Comprehensive genomic profiling (CGP), next-generation sequencing (NGS), Cancer genomics

    Received: 07 Jun 2024; Accepted: 04 Oct 2024.

    Copyright: © 2024 Strickland, Nesline, Previs, Ko, Cooper, Rushton, Wallen, Pabla, Conroy, Sausen, Saini, Cantini, Jensen, Caveney, Eisenberg, Severson and Ramkissoon. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Kyle C. Strickland, Labcorp Oncology, Durham, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.